Being selected by the EIC to join their delegation at BIO International Convention is a strong validation of our technology and clinical progress, and reflects the growing international interest in our work. BIO is a key meeting point for the global biotech community and provides an important platform to increase our visibility, build new relationships and explore potential partnering opportunities.

The capital enables us to continue advancing the ongoing clinical study and to take the next step in our development programme. Over the past year, we have reached several important milestones, including treating patients, generating initial safety data and receiving regulatory approvals. We are also seeing encouraging signals in our exploratory data. We now look forward to intensifying preparations for the next stage of clinical development.

Having our technology used in research published in Cell is a clear endorsement of its scientific quality. For Neogap, this is about building a long-term, relevant technology and IP platform, where strong academic collaborations are a key component.

Collaborating with Weill Cornell Medicine is an important step in our international development. It allows us to connect Neogap’s clinical progress in Sweden with leading US expertise in cell therapy and translational oncology. This project not only prepares us for future clinical trials in the United States but also reinforces the global relevance of our novel personalised immunotherapy.

We’re looking forward to applying our tumor-draining lymph node T-cell expertise to investigate a potential strategy to directly impact personalized treatment for patients with solid cancers.

Strong international IP protection is critical as we advance in clinical development – not only to enable future partnerships, but to reinforce the global credibility of our technology. Patent protection in China, one of the world’s largest and fastest-growing life science markets, also supports our long-term ambition to deliver innovative therapies for patients with hard-to-treat cancer.

Neogap is developing a personalised cell therapy that addresses one of the greatest challenges in modern oncology – the ability to selectively target the unique mutations of a tumour. By using a patient’s own T cells and training them to recognise the tumour-specific targets, the therapy creates a targeted treatment with the potential to cure patients who currently have no remaining treatment options. This is particularly relevant in colorectal cancer, a major disease with rising incidence, especially among younger patients. I look forward to contributing to the company’s continued development.

Jonas brings clinical expertise and an international perspective with deep roots in advanced cell therapy. His experience will be of great value as we progress in our clinical development programme and strengthen the company for the next stages.

The EpiTCer® technology is very powerful, as it not only enables efficient delivery of neoantigens to the immune system and selective expansion of tumour-specific T cells, but also provides us with the tools to functionally assess the potency of our therapy. This combination makes Neogap’s approach unique within cell therapy.

Being able to give the full dose from the outset is an important step in the development of our personalised cell therapy. It allows us to collect data earlier that may contribute to the evaluation of both the treatment’s safety and efficacy, while supporting a more efficient and flexible study design – to the benefit of both patients and our continued development efforts.

Being selected for the EIC Soft-landing Programme is a strong validation of the relevance of our technology in a global innovation context. This programme offers us a concrete opportunity to strengthen our presence in the US market and build new relationships

We are honoured to have been selected for Innovate Nordics 2025. The programme offers us a valuable opportunity to strengthen existing relationships, build new ones, and increase our access to the U.S. market. Each step we take brings us closer to our goal – making personalised cancer immunotherapy available to more patients.

Safety data from the first two treated patients confirm that Neogap’s immunotherapy is well tolerated and further strengthen our confidence in its potential as a valuable treatment option for patients with difficult-to-treat cancer. The trial is progressing as planned, and we continue to gather data to assess the safety profile and analyse clinical outcomes and biomarkers as part of the exploratory evaluation.

We are very excited to have been selected for this significant grant from ScaleReady and look forward to incorporating the G-Rex platform into our pTTL manufacturing process. Our development team has already completed preliminary experiments, and this grant will allow us to continue the development of a robust and cost-effective bioreactor process required to meet our quality and safety standards for clinical production, bringing us closer to our goal of delivering personalised medicine to patients in need.

The results demonstrate that PIOR® can effectively identify neoantigens with potential for future therapeutic applications. Data-driven analysis of neoantigens is an important component of the new generation of personalised cancer immunotherapies.

This study aligns with Neogap's vision to develop the next generation of cell therapies. PIOR® plays a key role in our efforts to identify the most promising neoantigens—an essential part of the development of future precision therapies.

We are delighted to have treated the first patients – this is a significant milestone in our clinical trial and our mission to develop curative treatments for critically ill cancer patients. We have an outstanding trial team and look forward to the upcoming results.

The ATMP classification is a strong validation of our innovative approach and pTTL's potential as a breakthrough cancer therapy. It provides regulatory clarity and invaluable guidance from the EMA, enabling us to advance development efficiently and effectively. We are now well-positioned to continue our work towards delivering transformative treatments to cancer patients.

Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance.

With the newly granted patent in China, we are not only strengthening our international position in biotechnology but also expanding the applications of our EpiTCer® technology. While our primary focus remains on developing cancer treatments, this patent also opens new avenues for the treatment and diagnosis of MS. It demonstrates our ability to successfully expand our research areas to include other serious health conditions, contributing to our capacity to offer even more effective solutions for combating both cancer and autoimmune diseases.

We are very grateful for Eurostars' backing, which not only recognises the scientific potential of our company but also reinforces our role as an innovator in analysis methods for next-generation cell therapies. The funding enables further research that is essential for advancing our cell therapy product to later clinical phases.

The new patent marks a milestone that not only strengthens our IP portfolio but also reflects the great potential of our EpiTCer® platform. While our primary focus remains on cancer treatment, this patent also signifies an exciting expansion of our research into other vital areas, including MS, where we see considerable potential for our EpiTCer® technology. This development allows us to build further on our previous successes in identifying specific molecular markers for MS diagnosis and take an important step forward in our research and development of innovative treatments for autoimmune diseases.

These capital injections are a clear endorsement of the innovative spirit and dedicated efforts that define Neogap's work. The EU funding confirms our ambition to be a driving force in the field of cancer therapy. With these resources, we can continue our development work as planned, bringing us closer to our long-term objective – to improve treatment options and increase the survival chances for cancer patients.

We are very pleased and proud to see that Neogap was selected as one of the most promising Swedish companies by the Catalyst committee. We look forward to collaborating with Business Sweden, exploring strategic international partnerships, and finding potential investors in our innovative cell therapy pTTL.

We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in Neogap. This acquisition marks a momentous milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment.

We are pleased that Neogap has been granted this patent in Europe. Our continuous evaluation of intellectual property rights ensures the protection of our unique cancer therapies. Our focus is to develop our treatments for personalised immunotherapy, to increase survival rates and improve the quality of life for cancer patients.

We are delighted, not only because the acquired knowledge can be harnessed to develop personalised therapies for the lifelong suffering associated with multiple sclerosis, but also because we have obtained additional evidence that our technology platform holds substantial relevance across multiple disease fields, encompassing autoimmune disorders and other immune-related conditions. We are committed to advancing pioneering applications for EpiTCer® and making significant contributions to developing novel therapies for treating severe illnesses.

Enrolling the first patient in our Phase I/II clinical trial is a momentous occasion for Neogap. We are both humbled and excited by this achievement. It signifies our dedication to advancing cancer treatment by enhancing the immune system's tumour-specific responses, ultimately increasing overall survival. I am immensely proud of our team's hard work and determination. This important transition propels Neogap into a clinical-stage company, bringing us closer to realising our vision of delivering effective treatment for solid cancers.

We are delighted to welcome Alejandro Fernandez Woodbridge to our team. With over two decades of experience in bioinformatics and software development, his distinguished background will be invaluable for further development of PIOR® in the field of cell therapy and diagnostics.

We are thrilled to contribute to and be a part of Cellerys upcoming Phase II study, where EpiTCer® will be a key aspect in monitoring autoreactive T cells. The collaboration with Cellerys opens up opportunities for Neogap to use our technology platform in several disease fields, including autoimmune diseases and other immune-related conditions. Our goal is to continue to develop innovative applications for EpiTCer® and contribute to the development of new therapies for the treatment of severe diseases.

We are thrilled to welcome Dr. Hanjing Xie as our new Chief Medical Officer. With extensive experience in research, clinical development, and patient care, Dr. Xie brings a wealth of expertise to Neogap. Her diverse background in the pharmaceutical industry and academia, along with specialised training in clinical oncology, and hematology, make her highly qualified to lead our cell therapy trial.

Our technology PIOR® is a safe and regulated system for bioinformatic analysis of sequencing data that is also user-friendly. This provides the advantage of securely handling patient data while having the potential for multiple future applications in diagnostics and precision medicine. The collaboration with Simsen is an important step in expanding the PIOR® technology towards future commercialization and out-licensing of PIOR®, which is very exciting for us.

The approval and the prompt initiation of the clinical trial represent significant milestones for Neogap. We have demonstrated that we can take an advanced cell therapy product from preclinical to clinical development. I am very proud of our skilled and committed team who, together with experienced partners, have brought us to this important point. As a result, we are now taking a big step towards our goal of curing cancer patients who would otherwise not survive.

We are very pleased that we have got a Notice of Allowance in Europe for this patent application which adds increased value to our immune-oncology pipeline and strengthens NEOGAP's patent portfolio.

We would like to extend a warm welcome to Anna Kälvemark and Steve Glavas to Neogap's board. They are an ideal complement to Neogap's board at a stage when we are about to enter the clinical phase.

By identifying a patient's personal autoantigen profile, treatment can be adapted for that particular individual. T cells drive most autoimmune diseases, and if we can find a way to silence them in a disease such as MS, it can pave the way for a more precise way to treat other autoimmune diseases as well.

The results demonstrate the potential of our EpiTCer® technology and further strengthen our belief that the choice of neoantigens, and how to administer them, are critical parameters for the production of potent, tumour-targeted T cells and the foundation for successful immunotherapeutic treatment.